Baqsimi ® (glucagon) nasal powder


This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BAQSIMI™ (glucagon) nasal powder: Contraindications

Baqsimi (glucagon nasal powder) is contraindicated in patients with pheochromocytoma, insulinoma, or known hypersensitivity to glucagon or to any of the excipients.

Detailed Information

Baqsimi is contraindicated in people with

  • pheochromocytoma because of the risk of substantial increase in blood pressure

  • insulinoma because of the risk of hypoglycemia, and

  • known hypersensitivity to glucagon or to any of the excipients in Baqsimi.1

Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.1

Enclosed Prescribing Information

BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly


1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.


Baqsimi = Baqsimi™ (glucagon) nasal powder

Date of Last Review: November 16, 2020

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical